Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

Newell, Pippa; Toffanin, Sara; Villanueva, Augusto; Chiang, Derek; Minguez, Beatriz; Cabellos, Laia; Savic, Radoslav; Hoshida, Yujin; Lim, Kiat; Melgar-Lesmes, Pedro; Yea, KEMAL; Peix, Judit; Deniz, Kemal; Fiel, M.; Thung, Swan; Alsinet, Clara; Tovar, Victoria; Mazzaferro, Vincenzo; Bruix, Jordi; Roayaie, Sasan; Schwartz, Myron; Friedman, Scott; Llovet, Josep

doi:10.1016/j.jhep.2009.03.028

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

Newell P., Toffanin S., Villanueva A., Chiang D. Y., Minguez B., Cabellos L., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.51, sa.4, ss.725-733, 2009 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 51 Sayı: 4
Basım Tarihi: 2009
Doi Numarası: 10.1016/j.jhep.2009.03.028
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.725-733
Anahtar Kelimeler: Liver cancer, HCV, Signaling pathway, Molecular therapies, Ras, mTOR
Erciyes Üniversitesi Adresli: Evet

Özet

Background/Aims: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.